Formulating Hope for Hard-to-Treat Patients

At Handa, we collaborate with our partners to turn formulation science into new therapies for patients that today’s treatments leave behind.

At Handa Pharma, we harness the full transformative power of formulation science, creating precision medicines that deliver hope for hard-to-treat patients.

Product Announcement

Gray and green Omcazio™ logo

OMCAZIO is a kinase inhibitor indicated for the treatment of RCC and HCC.

Product Announcement

Now Available

Purple and green Phyrago® logo
An FDA-approved dasatinib therapy for adults and children with Ph+ leukemias.

Who We Are

Handa Pharma develops stable, effective, high-quality prescription medications to serve challenging, high-barrier markets.

These are the spaces where Handa delivers value and a durable advantage for patients, partners, and our team. Where we fully leverage our deep knowledge and experience navigating pharma’s complex R&D, marketing, licensing, and regulatory environment.

In the U.S. and China, two of the world’s largest pharmaceutical markets, Handa shepherds complex products from concept, through FDA review and approval, to successful commercialization and adoption.

Handa is headquartered in the San Francisco Bay Area, with a global R&D hub in Taiwan.

Our four wholly owned subsidiaries are:

Help Us Create Next-generation Medicines

We’re looking for partners to join us in the vanguard of formulation science, helping to deliver new, effective medicines for hard-to-treat patients.